Herpes simplex virus (HSV) entry requires host cell 26S proteasomal degradation activity at a postpenetration step. When expressed in the infected cell, the HSV immediate-early protein ICP0 has E3 ubiquitin ligase activity and interacts with the proteasome. The cell is first exposed to ICP0 during viral entry, since ICP0 is a component of the inner tegument layer of the virion. The function of tegument ICP0 is unknown. Deletion of ICP0 or mutations in the N-terminal RING finger domain of ICP0 results in the absence of ICP0 from the tegument. We show here that these mutations negatively influenced the targeting of incoming capsids to the nucleus. Inhibitors of the chymotrypsin-like activity of the proteasome the blocked entry of virions containing tegument ICP0, including ICP0 mutants that are defective in USP7 binding. However, ICP0-deficient virions were not blocked by proteasomal inhibitors and entered cells via a proteasome-independent mechanism. ICP0 appeared to play a postpenetration role in cells that supported either endocytosis or nonendosomal entry pathways for HSV. The results suggest that ICP0 mutant virions are defective upstream of viral gene expression at a pre-immediate-early step in infection. We propose that proteasome-mediated degradation of a virion or host protein is regulated by ICP0 to allow efficient delivery of entering HSV capsids to the nuclear periphery.
Herpes simplex virus (HSV) engages the host cell machinery in a coordinated manner during the initial stages of infection. 26S proteasomes are ϳ2.5 MDa, ATP-dependent multisubunit proteolytic machines present in both the nucleus and the cytoplasm of all eukaryotic cells (58, 64) . The proteasome executes the controlled degradation of functional proteins, as well as the hydrolysis of aberrantly folded polypeptides. Proteins that are tagged with chains of the 76-amino-acid protein ubiquitin are targeted for degradation by the proteasome. Viruses commandeer proteasome activity to promote many aspects of the viral life cycle (60) , including viral entry. Herpesviral entry can be broadly defined as all events leading to the deposition of the uncoated virus genome into the nucleus. Functional proteasomes facilitate HSV entry at a postpenetration stage (14) . Inhibitors of the proteasome impair incoming HSV capsid transport to the nuclear periphery but do not affect cell attachment, penetration, or membrane fusion. The proteasome dependence of HSV entry does not rely on active host or viral protein synthesis. Thus, the proteasome is important for a pre-immediate-early event in HSV infection, i.e., a step that occurs after penetration but prior to viral immediate-early gene expression.
Infected cell protein 0 (ICP0), the HSV E3 ubiquitin ligase, is a 110-kDa, multifunctional phosphoprotein that is expressed with immediate-early (IE) kinetics. It is a global transactivator of viral and cellular genes and is required for productive lowmultiplicity infection (8, 24, 57, 63) . ICP0 interactions with the ubiquitin-proteasome system are well documented. For example, it mediates the degradation of several cellular proteins (28, 38) , induces conjugation of ubiquitin (23) , and sequesters proteasomes in the nucleus (41) . The amino-terminal, zinc-binding, RING finger domain is required for many of ICP0's known functions and has E3 ubiquitin ligase activity (4, 20, 21) .
In addition to its expression in infected cells, ICP0 is also a minor structural component of the virion tegument, present at 100 to 200 copies per virion (42, 68) . Virion ICP0 is considered an inner tegument protein because it is tightly associated with capsids (15) . The RING finger is required for incorporation of ICP0 into the inner tegument layer, as is the N terminus of VP22 (15, 45) . The role of ICP0 as an abundantly expressed IE protein has been well studied, but no function has been ascribed to tegument ICP0 or to another virion IE protein ICP4, which is an outer tegument component (15) . Since HSV entry and ICP0 are both functionally linked to the proteasome, we investigated the involvement of capsid-associated ICP0 in proteasome-dependent viral entry. We report that incoming capsids from virions that lack tegument ICP0 were aberrantly targeted and that the entry of ICP0-deficient viruses was resistant to proteasome inhibitors.
promoter (65) . Wild-type Glasgow strain 17 syn ϩ (17 ϩ ) (5) and its ICP0 mutant derivatives were provided by R. Everett, MRC Virology Unit, Glasgow, United Kingdom. The mutant dl1403 virus has a 2-kb lesion in ICP0 (63) . The FXE virus has a defined lesion in the ICP0 RING finger domain (20) (21) (22) 29) . Rescued dl1403 and FXE viruses were obtained by transfection of mutant virion DNA with a plasmid containing a fragment specifying the ICP0 gene (22, 56) . The K144E and N155D viruses have single amino acid substitutions in the alpha helix of the ICP0 RING finger (19) . M1 virus has a double amino acid substitution in ICP0 that reduces USP7 interaction (27) . D12 has a deletion in the ICP0 C terminus that inhibits USP7 binding (47) . Rescued M1 virus was obtained by transfection of mutant virion DNA with a fragment of the ICP0 gene that includes the M1 mutations (3).
Chemicals. Stocks of 0.5 M cycloheximide (Sigma) and 10 mM TPCK (Ntosyl-L-phenylalanine chloromethyl ketone; Fisher Scientific) were prepared in ethanol. E-64d (5 mM; Sigma) was prepared in methanol, and 1 mM lactacystin (Peptides International), 0.2 mM YU102 (Biomol International, Plymouth Meeting, PA), 4 mM MG132 (Sigma), 5 mM TLCK (N-p-tosyl-L-lysine chloromethyl ketone; Sigma), 1 mM pepstatin A (Sigma), 10 mM phosphoramidon (Sigma), 4 mM leupeptin, and 25 mM CA-074 (Sigma) were prepared in dimethyl sulfoxide (Sigma). All stocks were stored at Ϫ20°C.
Antibodies. Mouse monoclonal antibody (MAb) 11060, which is specific for the exon 2 sequences of ICP0, was kindly provided by R. Everett (25) . MAb H1A027 to ICP0 and MAb HA018 to VP5 were purchased from Virusys (North Berwick, ME).
SDS-PAGE and Western blotting. Samples in Laemmli buffer were separated by SDS-PAGE and blotted onto nitrocellulose. Membranes to be probed with MAb 11060 were first treated with Qentix Western blot signal enhancer according to the manufacturer's instructions (Thermo Scientific). After the addition of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (Pierce, Rockford, IL), enhanced chemiluminescence substrate was added (Pierce), and blots were exposed to X-ray film (Kodak).
Beta-galactosidase reporter assay for HSV entry. Confluent CHO-nectin-1 cell monolayers grown in 96-well dishes were treated with medium containing proteasome inhibitors or vehicle controls for 30 min at 37°C. Virus (multiplicity of infection [MOI] of 1) was added, and cells were incubated in the constant presence of agent for 6 h. Then, 0.5% Nonidet P-40 (Sigma) cell lysates were prepared, chlorophenol red-␤-D-galactopyranoside (Roche Diagnostics, Indianapolis, IN) was added, and the beta-galactosidase activity was read at 595 nm with an ELx808 microtiter plate reader (BioTek Instruments, Winooski, VT). The beta-galactosidase activity indicated successful entry. Mean results and standard errors were calculated for four replicate samples.
Subcellular localization of HSV capsids during entry. Vero cells were grown overnight on glass coverslips in 24-well dishes. Cells were treated with proteasome inhibitor or vehicle control in the presence of 0.5 mM cycloheximide for 15 min at 37°C. Cultures were rapidly chilled on ice, and then parental or mutant virus was added (based on equivalent particle numbers) in the continued presence of agent. Virus was spinoculated onto the cell surface by centrifugation at 200 ϫ g for 1 h at 4°C. Cells were washed with phosphate-buffered saline (PBS), and then warmed medium containing the indicated drugs was added. Infection proceeded for 2.5 h in the presence of cycloheximide. Cells were washed two times with PBS and fixed in methanol for 20 min. Coverslips were air dried and blocked with PBS containing 1% bovine serum albumin for 10 min. Virion capsids were visualized by staining with mouse MAb HA018 to HSV-1 VP5, followed by an Alexa 488-labeled goat anti-mouse secondary antibody (Molecular Probes, Eugene, OR). Nuclei were counterstained with DAPI (4Ј,6Ј-diamidino-2-phenylindole; Roche). Coverslips were washed with PBS, mounted with Fluoromount G (Electron Microscopy Sciences), and viewed with an Olympus 1X81 spinning-disk confocal microscope equipped with a 63ϫ oil immersion objective lens. Digital images were processed with Adobe Photoshop CS2 version 9.
RESULTS
HSV entry is blocked by inhibitors of the chymotrypsin-like activity of the 20S proteasome. In addition to the proteolytic activities of the 20S proteasome, other cellular proteases can play important functions in viral entry. We screened inhibitors of several different classes of mammalian proteases for their effects on HSV entry. We used an HSV-induced beta-galactosidase reporter assay, which is commonly used to assess HSV entry. E-64d and leupeptin are broad-spectrum endosomal cysteine protease inhibitors that reduce cathepsin-mediated entry of Ebola virus and severe acute respiratory syndrome (SARS) coronavirus, respectively (11, 61) . CA074 is a narrow-spectrum inhibitor of cathepsin B that inhibits Ebola entry (11) . TLCK inhibits trypsin-like serine proteases. Pepstatin A and phosphoramidon selectively inhibit aspartic acid proteases and metalloproteases, respectively. Lastly, lactacystin, a Streptomyces metabolite, inhibits proteasome-mediated proteolysis and blocks HSV entry (14) . The inhibitors were tested at concentrations known to block cellular enzymatic activity and did not affect cell viability. Of these protease inhibitors, lactacystin was the only one to block HSV entry into CHO-nectin-1 cells under the conditions tested (Fig. 1A) .
Three distinct proteolytic activities line the channel of the 20S proteasome and are responsible for degradation. Based on the nature of the active sites, the activities are designated chymotrypsin-like, trypsin-like, and caspase-like. We tested the effect of specific inhibitors of each of these catalytic sites on HSV entry. TPCK, TLCK, and YU102 inhibit the proteasomal chymotrypsin-, trypsin-, and caspase-like activities, respectively. TPCK inhibited HSV entry in a concentration-dependent manner. TLCK and YU102 had no inhibitory effect at the concentrations tested (Fig. 1B) . Together with previous results (14) , this indicates that the chymotrypsin-like activity, which is located on the beta 5 subunit of the 20S catalytic core, is important for HSV entry.
Reduced capsid transport to the nucleus in the absence of tegument ICP0. To begin to address the impact of virion ICP0 on HSV entry, we analyzed HSVs bearing mutations in the ICP0 gene (Table 1) . Viruses with ICP0 deletions or with mutations in the RING domain are defective in initiating HSV gene expression and have reduced titers. Notably, FXE and K144E mutant virions do not contain ICP0 in the virion tegument, but N151D virions contain wild-type levels of ICP0 (15) . Capsids of wild-type HSV accumulate at the nuclear periphery by 1 to 2.5 h postinfection (p.i.) (1, 50, 62) . We monitored the transport of incoming capsids from ICP0 mutant viruses with immunofluorescence and confocal microscopy. Cycloheximide treatment ensured that no new viral protein synthesis occurred.
At 2.5 h p.i., the majority of wild-type 17ϩ and N151D capsids were detected at or around the nucleus. ( Fig. 2A and E). In contrast, for dl1403, FXE, and K144E viruses, the majority of capsids were distributed in the cytosol and cell periphery as opposed to the nuclear periphery ( Fig. 2B to D) . At high multiplicities, these mutant viruses are competent for replication, so infectious genomes ultimately must be delivered to the nucleus. However, the bulk of capsids entering in the absence of virion ICP0 appear to have a defect in transport. Thus, tegument ICP0 may influence incoming particle delivery to the nuclear periphery. The results support the notion that defects in the infectivity of ICP0 mutant viruses may be partly explained by the absence of ICP0 from the tegument of entering viral particles.
Entry of ICP0 mutant virions is resistant to inhibition by MG132. Incoming capsid delivery to the nuclear periphery is facilitated by proteasome activity (14) . Since virion ICP0 is capsid-associated and appears to influence capsid targeting during entry (Fig. 2) , we analyzed the role of proteasome activity in the entry of ICP0 mutant viruses. Successful entry of ICP0-null viruses is measurable by beta-galactosidase reporter assay, albeit to reduced levels relative to the wild type (51) (see Fig. 4D ). MG132 is a peptide aldehyde that inhibits the chymotrypsin-like activity of the proteasomal 20S catalytic core (39) . MG132 blocked Vero cell entry of HSV-1 KOS-tk12 (Fig.  3A) , which is wild type for ICP0. HSV-1 KOS 7134 lacks both copies of ICP0 and was not readily inhibited. In previous studies of the proteasome and HSV entry, the HSV-1 strain KOS strain was used (14) . In the present study, we utilized several FIG. 2. Subcellular localization of entering virions that lack tegument ICP0. HSV-1 17ϩ (A), dl1403 (B), FXE (C), K144E (D), or N151D (E) was added to Vero cells in the presence of 0.5 mM cycloheximide. Inocula contained equivalent VP5 units, as determined by protein staining of each virus preparation, corresponding to an MOI of 10 for wild-type 17ϩ. At 2.5 h p.i., the cells were fixed, and capsids were visualized with antibody HA018 to VP5, followed by Alexa 488 secondary antibody. Nuclei were stained with DAPI. For panels A and E, the focus was at the nuclear membrane. For panels B to D, the focus was close to the coverslip. Images are representative of the cell population from at least two independent experiments. Bar, 100 m.
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on November 3, 2017 by guest http://jvi.asm.org/ ICP0 mutant viruses that were constructed in a wild-type HSV-1 strain 17ϩ background. To confirm that 17ϩ entry was also proteasome dependent, we added KOS or 17ϩ to CHOnectin-1 cells in the presence of MG132 and then measured beta-galactosidase activity. KOS and 17ϩ were inhibited in a very similar concentration-dependent manner (Fig. 3B) . HSV-1 dl1403 is an ICP0 deletion mutant derived from 17ϩ. Interestingly, entry of dl1403 into CHO-nectin-1 cells was refractory to inhibition by MG132, whereas 17ϩ and the rescuant dl1403R (Fig. 4A) were readily inhibited. This suggests that ICP0 influences the proteasome dependence of HSV entry. Importantly, dl1403-infected cells produced beta-galactosidase in the presence of up to 50 M MG132 (Fig. 4A) , suggesting that MG132 does not directly inhibit reporter gene expression in this assay. This is consistent with the notion that MG132 blocks wild-type HSV entry at the level of capsid transport (14) .
The N-terminal RING finger domain of ICP0 is essential for many of ICP0's functions and determines incorporation of ICP0 into the tegument of extracellular virions. The HSV-1 FXE mutant encodes ICP0 with its RING domain deleted. Entry of FXE was resistant to inhibition by MG132 relative to 17ϩ and the rescuant FXER (Fig. 4B) , both of which were readily inhibited. Despite wild-type levels of virion ICP0 (15), the dl1403R and FXER rescuants appeared to be slightly more resistant than wild type to the lower concentrations of MG132 (Fig. 4A and B) . The HSV-1 K144E and N151D mutants have substitution mutations in the predicted alpha helix of the RING finger. ICP0 with the K144E mutation, but not N151D, is incorporated into the virion tegument layer (15) . Entry of N151D was inhibited by MG132, but K144E was more resistant to inhibition relative to wild type (Fig. 4C) . In all, the results in Fig. 4A to C suggest that initiation of infection by HSV that is deficient in tegument ICP0 is to an extent proteasome-independent.
In these experiments, entry was measured at an MOI of 1. When compared at a range of MOIs in the absence of inhibitor, the ICP0-null virus dl1403 induced less beta-galactosidase expression relative to the wild type (Fig. 4D) . The defect was more pronounced at lower MOIs. Beta galactosidase expression by the CHO-nectin-1 cells is controlled by the ICP4 promoter. Wild-type and ICP0-null virions are equally efficient at activating the ICP4 promoter (7, 8) , and ICP0-null virions contain wild-type levels of VP16 (15) . Thus, reporter gene expression in these cells is largely driven by VP16. We favor the interpretation that ICP0-deficient virions have reduced reporter gene expression due to a defect in viral entry ( Fig. 2 and Fig. 4D) .
Entry of wild-type 17ϩ at a low MOI of 0.1 resulted in greatly reduced beta-galactosidase activity (Fig. 4D) . Despite different levels of reporter gene expression, 17ϩ was inhibited to a similar extent by MG132 at MOIs ranging from 0.1 to 100 (data not shown). This suggests that entry is proteasome dependent regardless of the MOI as long as ICP0 is present. The level of input ICP0 may not affect the requirement of the proteasome. ICP0-deficient viruses have high particle/PFU ratios, up to a log greater than that for the wild type on U2OS cells (7, 63, 69; unpublished data) . This raises the possibility that the resistance of ICP0 mutant viruses to MG132 in Fig. 3A and 4 may be due to fewer infectious virions in the inocula. However, this was not the case because increasing the amount of infectious particles by using an MOI of 10 resulted in ICP0-null virus entry that is similarly refractory to MG132 (data not shown). Thus, the proteasome independence of ICP0-deficient virus entry appears to be independent of MOI. This contrasts with the more critical role of IE ICP0 in low-rather than high-multiplicity infections. Wild-type virus-infected cells in the presence of MG132 to an equivalent extent as ICP0-null virus in untreated cells. This supports the notion that the presence of ICP0 correlates with proteasome-mediated entry.
ICP0-null HSV enters cells via a pH-dependent, endocytic pathway. Wild-type HSV entry into CHO-nectin-1 cells is blocked by inhibitors of endosome acidification (50) . CHOnectin-1 cells are a prototype cell line for endosomal entry, which may be mediated by pH-triggered conformational change in the fusion protein gB (17) . Since the role of the proteasome in the entry of ICP0-null HSV appears to be distinct from the wild type, we determined the cellular entry pathway used by dl1403 in CHO-nectin-1 cells. Ammonium chloride, which elevates the normally low pH of endosomes, blocked the entry of HSV-1 dl1403 in a concentration-dependent manner similar to the wild type (Fig. 5) . Thus, the absence of ICP0 does not affect the pH-dependent entry of HSV. Proteasome activity is also needed for entry via either cellular pathway, likely at a postfusion step (14) . Entry of ICP0-null mutants into either Vero or CHO-nectin-1 cells is refractory to inhibition by MG132 ( Fig. 3 and 4) . Together, the data suggest that tegument ICP0 may play a postpenetration role in HSV entry in cells that support nonendocytic or low pH endocytic routes.
Role of the USP7 interaction domain of ICP0 in the proteasome-dependent entry of HSV. During HSV infection ICP0 binds to the host ubiquitin-specific processing protease 7 (USP7), also known as herpesvirus-associated ubiquitin-specific protease (HAUSP) (28) . ICP0 amino acids 593 to 633 comprise the binding domain. Interacting with USP7 may stabilize ICP0 by protecting it from autoubiquitination and proteasome-mediated degradation (3, 10) . M1 and D12 contain mutations in the binding domain that ablate USP7 interaction (Table 1) . In order to determine the impact of this domain on proteasome-dependent entry, we first determined whether these mutant ICP0s were incorporated into the tegument layer. M1 and D12 virions contained levels of ICP0 similar to wild- (Fig. 6A ). This suggests that USP7 interaction with ICP0 is dispensable for the association of ICP0 with mature virions. Similar results indicating incorporation of M1 and D12 mutants into virions were reported (45) while the present report was in preparation. Entry of M1 and D12 viruses was inhibited by MG132 in a concentrationdependent manner (Fig. 6B ). M1 and D12 had slightly higher IC50s for MG132 than wild type and the M1 rescuant, but at the highest concentrations tested, both USP7-binding mutant viruses were inhibited like wild type. The USP7 interaction domain of ICP0 appears to have little effect on the proteasome-dependent entry of HSV. Effect of MG132 on subcellular localization of incoming capsids from virions that lack tegument ICP0. We analyzed the effect of inhibiting proteasome activity on the capsid targeting of viruses with ICP0 mutations, noting that virions that lacked ICP0 already have defective localization (Fig. 2) . N151D contains tegument ICP0 and, in untreated cells, its capsids are targeted to the nucleus in a manner similar to the wild type (Fig. 2) . In the presence of MG132, the majority of capsids from entering N151D virions were detected in the cell periphery (Fig. 7E) , indicating that proteasome activity facilitates their transport. In the absence of MG132, capsids were detected at or near the nuclear rim ( Fig. 2A and data not shown) (14) . Entering capsids from virions that are deficient in tegument ICP0 (dl1403, FXE, and K144E) were distributed throughout the cytosol of cells treated with MG132, including the nuclear periphery and at intermediate sites between the cell periphery and nucleus (Fig. 7B to D) . Their distribution was not readily distinguishable from that of untreated cells. Thus, in the absence of tegument ICP0, entering capsids display aberrant targeting regardless of whether proteasomes are active. However, these ICP0 mutant virions do successfully infect the cells, albeit to a lesser extent than the wild type. Together, the results suggest that HSV that lacks tegument ICP0 can successfully infect cells via a proteasome-independent pathway. In the presence of virion ICP0, entering capsids are targeted to the nuclear periphery via a proteasome-dependent pathway. Thus, tegument ICP0 may play a pre-immediate-early, regulatory role in HSV entry at the level of capsid targeting to the nucleus.
DISCUSSION
Functional proteins within the tegument layer of herpes simplex virions are exposed upon cell entry after the viral envelope fuses with a host cell membrane. The minor virion component, ICP0, is a capsid-associated, inner-tegument protein. We demonstrate here that mutant virions that fail to incorporate ICP0 into the tegument were defective in capsid transport from the cell periphery to the nucleus. Entry of virions that contain tegument ICP0 was blocked by inhibitors of the chymotrypsin-like activity of the proteasome at the level of capsid delivery to the nucleus. In contrast, ICP0-deficient virions entered cells in a proteasome-independent manner. Together, the results suggest a newly described role for the multifunctional ICP0 during the earliest stages of viral infection, prior to viral gene expression. We propose that tegument ICP0 regulates the proteasome-dependent delivery of entering capsids to the host cell nucleus. This may represent the first function ascribed to the ICP0 structural component of the virion.
Viruses utilize host proteasome activity to promote viral entry, gene expression, replication, assembly, and egress. Inhibitors of the proteasome block the entry of several viruses including influenza, coronaviruses, parvoviruses, and HSV (2, 14, 53, 66) . We propose a role for a viral protein, ICP0, in the regulation of proteasome-mediated entry. The proteasomedependent step in the entry of several viruses appears to be at the level of endocytic uptake. HSV capsid transport depends on the proteasome regardless of whether an endosomal or nonendosomal pathway is used. ICP0 appears to regulate entry into both CHO-nectin-1 and Vero cells, which support endocytic and nonendocytic entry, respectively, which is consistent with ICP0 impacting a postpenetration, pre-immediate-early event.
Interplay of IE ICP0 and the ubiquitin-proteasome system in infected cells. The functional activities of ICP0 synthesized by the infected cell have been studied intensively. ICP0 is pivotal in the switch between lytic and latent infections. ICP0 also inhibits the antiviral response to cellular interferons (48) and may help the virus bypass innate cellular repression pathways (32) . Early in infection, it dynamically interacts with proteasomes in the nucleus, where it is responsible for proteasome-mediated degradation of nuclear subdomains called ND10 (12, 26) . The RING finger mediates ND10 dissociation, which is thought to facilitate HSV gene expression (24, 33) . Another potential mechanism for alteration of gene expression is ICP0 interaction with host cell histone deacetylases (52, 70) . Early in infection, MG132 treatment prevents ICP0 export to the cytosol and results in nuclear retention. When added late in infection, MG132 causes cytosolic ICP0 to translocate to the nucleus (41) . ICP0 also induces the conjugation of ubiquitin in a RING finger-dependent manner (23) and is required for the sequestration of proteasomal components in discrete nuclear foci (6) . In the presence of MG132, ICP0 can associate with proteasome subunits in the nucleus (41) .
ICP0 interacts with cellular proteins, including cyclin D3 (38), elongation factor 1␦ (37) , and the ubiquitin-specific protease USP7 (28) . We show in the present study that the C-terminal domain of ICP0 that interacts with USP7 is not required for ICP0 incorporation into virions. Entry of virions with the USP7 binding domain deleted is susceptible to proteasome inhibitors as measured by reporter assay. However, a role for USP7 in capsid transport cannot be ruled out. The subcellular fate of ICP0 brought into the cell with the entering virion and whether tegument ICP0 exerts any of the known effects of IE ICP0 remain to be determined.
HSV tegument and pre-immediate-early events in infection. After fusion of HSV with an endosomal membrane of epithelial cells or with the cell surface of neurons (44, 49, 50, 67) , the majority of the tegument layer dissociates from the capsid (46) . Capsids utilize the host motor complex dyneindynactin to travel on microtubules to the nuclear periphery (16) . Tegument components can affect pre-immediate-early events that occur after penetration but prior to immediateearly gene expression (35) . For example, upon release into the cell, the tegument protein Vhs mediates degradation of cellular mRNAs in the absence of de novo viral gene expression (54) . Whether ICP0 remains capsid-associated during transport to the nucleus is not known. At least two other inner tegument proteins, VP1/2 and UL37, are transported with capsids during entry (31, 43) . VP1/2 (1, 13, 34, 55), like ICP0 (the present study), appears to play a functional role in capsid targeting to the nucleus. Jovasevic et al. reported that TPCK blocked proteolytic processing of incoming VP1/2 and proposed that viral DNA release into the nucleus was in turn inhibited (34) . Our results with TPCK and additional inhibitors of the chymotrypsin-like activity of the proteasome suggest that the TPCK block to entry is upstream of binding to the nuclear pore complex (14; the present study and data not shown).
ICP0 is incorporated into virions during tegumentation of the capsids in the cytosol (18, 59) . ICP27, the N terminus of VP22, the C-terminal 180 residues of ICP0 and the RING domain are required for the incorporation of ICP0 into mature virions (15, 45, 59) . RING finger mutations result in retention of ICP0 in the nucleus, which likely explains why ICP0 is not incorporated into mature extracellular virions. We are investigating a direct role for the E3 ubiquitin ligase activity of the RING finger in capsid transport.
How might tegument ICP0 influence viral particle delivery to the nuclear periphery? The entry of ICP0-deficient virions is less susceptible to proteasome inhibitors. A minor fraction of wild-type entry may also occur by a mechanism that is resistant to proteasome inhibitors (Fig. 1, 3 , 4, and 6). Whether this is the same proteasome-independent route traversed by ICP0-deficient virions is not known. The altered targeting of capsids from ICP0-deficient virions that we observed in nonpolarized cultured cells may be particularly important in sensory neurons where capsids must traverse a relatively long distance from the innervating axon termini to the cell bodies of sensory ganglia. Virion ICP0 may regulate the proteasome-dependent delivery of capsids to the nucleus.
The N terminus of VP1/2 has ubiquitin-specific protease activity (36) . It is tempting to speculate about a functional interaction between the inner tegument proteins VP1/2 and ICP0 during entry. ICP0-null particles penetrate into the cytosol of Vero cells at wild-type levels (7), indicating that viruscell fusion is not influenced by ICP0. ICP0 may mediate proteasomal degradation of virion proteins or host cytoskeleton components to facilitate capsid movement. Interestingly, IE ICP0 has been proposed to interact with microtubules (40) . We are determining whether virion ICP0 itself is degraded. ICP0-null virions have a protein composition similar to that of the wild type. Specifically, the HSV proteins VP5, VP1/2, ICP4, VP16, VP22, VP13/14, gB, gD, gH, and gL are incorporated into extracellular virions in the absence of ICP0 (15). However, it is possible that virion structural proteins apart from ICP0 may be missing and that ICP0 has an indirect effect on capsid targeting.
The entry phenotypes of mutant virions that have been rescued with the wild-type ICP0 gene are restored to near wild-type levels (Table 1) . However, attempts to complement ICP0-null virions with tegument ICP0 by propagation on ICP0-expressing cells have been unsuccessful (data not shown). ICP0-deficient virions have lower plating efficiencies, which have been attributed to defects in gene expression. Our results suggest that the altered targeting of incoming capsids may contribute to the replication defect of ICP0 mutant viruses.
